Latest news
Novo Nordisk CFO Knudsen: Oral Wegovy Drives Market Expansion With 80% of Patients New to Obesity Drugs - finance.biggo.comfinance.biggo.com · Fri, 07 Aug 2026 15:09:00 GMT‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth - Fierce BiotechFierce Biotech · Fri, 07 Aug 2026 13:08:00 GMTNovo Nordisk’s CFO on the oral Wegovy rollout and beyond - Fierce BiotechFierce Biotech · Fri, 07 Aug 2026 12:42:20 GMTWeight loss drug Wegovy made Novo Nordisk Europe’s most valuable company. Finding its next blockbuster drug is proving difficult - FortuneFortune · Thu, 06 Aug 2026 12:31:00 GMTNovo executive sees Wegovy price dynamics in the US as expected - medwatch.commedwatch.com · Thu, 06 Aug 2026 07:00:00 GMTNovo CEO looks to speed up R&D as share drop shows gap with Lilly - ReutersReuters · Wed, 05 Aug 2026 15:33:40 GMTNovo Nordisk CFO: We are ahead of schedule in achieving our company-wide transformation goal of 8 billion Danish kroner in cost savings. - BitgetBitget · Wed, 05 Aug 2026 03:36:40 GMT